Menotropin Treatment with MENOPUR should be initiated under the supervision of a physician experienced in the treatment of fertility problems. There is great interindividual variation in the response of the ovaries to exogenous gonadotropins. In this case, it is impossible to establish a standard dosing schedule. The dosage must therefore be individually adapted on the basis of the ovarian response. MENOPUR can be given alone or in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist. Recommendations for dosage and duration of treatment may vary depending on the actual treatment protocol employed. Women with anovulation (including PCOS) The aim of MENOPUR treatment is to ensure the development of a single Graafian (mature follicle) follicle and release of the oocyte after administration of human chorionic gonadotropin (hCG). MENOPUR treatment should be started within the first 7 days of the menstrual cycle. The initial recommended dose of MENOPUR is 75 - 150 IU daily and this dose should be continued for at least 7 days. Subsequent doses should be adapted based on individual patient response based on clinical monitoring results (either ovarian ultrasound alone or concomitant measurement of estradiol levels). Dose adjustments should not be made more often than every 7 days. The recommended dose increase is 37.5 IU each time and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU. If the patient has failed to respond adequately with 4 weeks of therapy, that cycle should be discontinued and a new therapy should be initiated at a higher starting dose than in the abandoned cycle.
- Menotropin Treatment with MENOPUR should be initiated under the supervision of a physician experienced in the treatment of fertility problems. There is great interindividual variation in the response of the ovaries to exogenous gonadotropins. In this case, it is impossible to establish a standard dosing schedule. The dosage must therefore be individually adapted on the basis of the ovarian response. MENOPUR can be given alone or in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist. Recommendations for dosage and duration of treatment may vary depending on the actual treatment protocol employed. Women with anovulation (including PCOS) The aim of MENOPUR treatment is to ensure the development of a single Graafian (mature follicle) follicle and release of the oocyte after administration of human chorionic gonadotropin (hCG). MENOPUR treatment should be started within the first 7 days of the menstrual cycle. The initial recommended dose of MENOPUR is 75 - 150 IU daily and this dose should be continued for at least 7 days. Subsequent doses should be adapted based on individual patient response based on clinical monitoring results (either ovarian ultrasound alone or concomitant measurement of estradiol levels). Dose adjustments should not be made more often than every 7 days. The recommended dose increase is 37.5 IU each time and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU. If the patient has failed to respond adequately with 4 weeks of therapy, that cycle should be discontinued and a new therapy should be initiated at a higher starting dose than in the abandoned cycle.
There is no comment for this product, yet.